Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic Fibrosis
Clinical Pharmacokinetics · 2025
DOI: 10.1007/s40262-025-01516-1 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Pharmacokinetics, 2025. Verfasst von Paulette Magnas und 13 weiteren Autor:innen. Beteiligte Einrichtung: U1343, Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Inserm, Université Paris Cité, Paris, France. paulette.magnas@…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Benzodioxoles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: VLM.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: Elexacaftor-tezacaftor-ivacaftor (ETI), a combination of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, has become the therapeutic standard of care for most people with cystic fibrosis (pwCF). People with cystic fibrosis exhibit differences in CFTR genotypes and have important differences in phenotypic characteristics including age, body weight, pancreatic status, disease severity, and comorbidities. While these differences predict large interindividual variability (IIV) in ETI exposure, there is a unique dose regimen recommended for adults. This raises questions around the "one-dose fits all" strategy. OBJECTIVES: The aims of this study were to describe real-world population pharmacokinetics (Pop-PK) of ETI in adults with CF and identify factors associated with IIV. METHOD: As part of the ongoing French national observational cohort study the Pop-PK analysis included 552 plasma concentrations drawn routinely from 325 adults with CF. RESULTS: A one-compartment model with first order absorption and elimination best represented all three compounds, and an additional lag-time for elexacaftor PK data. Large IIV was observed in ETI, with an area under the curve (AUC0-24h for elexacaftor and tezacaftor, and AUC0-12h for ivacaftor) ranging respectively, from 58.7-422.9 mg⋅h/L; 38.0-207.7 mg⋅h/L and 4.9-64.9 mg⋅h/L. The main sources of IIV identified in the final ETI Pop-PK models were body weight, age, exocrine pancreatic insufficiency and CFTR genotype. CONCLUSION: This study established the first ETI Pop-PK analysis in adults with CF and identified several covariates that explain IIV. Therapeutic drug monitoring may be beneficial for patients with a small body weight, older ages, carrying one ETI-responsive CFTR variant or those with no exocrine pancreatic insufficiency and especially for patients who combine these characteristics. Therapeutic drug monitoring may also prove to be useful in individuals experiencing adverse events, in those with reduced effectiveness, or to help manage non-adherence issues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- U1343, Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Inserm, Université Paris Cité, Paris, France. paulette.magnas@aphp.fr.
- U1343, Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte, Inserm, Université Paris Cité, Paris, France.
- Unité de Recherche Clinique, Université Paris Cité Necker/Cochin, Hôpital Tarnier, Paris, France.
- Service de Pharmacologie Clinique, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre, Paris, France.
- CIC-1419 Inserm, Hôpitaux Cochin-Necker, Paris, France.
- Service de Pneumologie, Centre National de Référence de la Mucoviscidose, Hôpital Cochin, AP-HP, Paris, France.
Förderung
- VLM
Zitieren
APA
Magnas, P., Bouazza, N., Foissac, F., Froelicher Bournaud, L., Lui, G., Carlier, N., Da Silva, J., Fesenbeckh, J., Kanaan, R., Honoré, I., Martin, C., Treluyer, J. M., Burgel, P. R., & Benaboud, S. (2025). Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic Fibrosis. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01516-1
Vancouver
Magnas P, Bouazza N, Foissac F, Froelicher Bournaud L, Lui G, Carlier N, et al. Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic Fibrosis. Clinical Pharmacokinetics. 2025. doi:10.1007/s40262-025-01516-1
BibTeX
@article{Magnas2025,
author = {Magnas, Paulette and Bouazza, Naïm and Foissac, Frantz and Froelicher Bournaud, Léo and Lui, Gabrielle and Carlier, Nicolas and Da Silva, Jennifer and Fesenbeckh, Johanna and Kanaan, Reem and Honoré, Isabelle and Martin, Clémence and Treluyer, Jean-Marc and Burgel, Pierre-Régis and Benaboud, Sihem},
title = {Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic Fibrosis},
journal = {Clinical Pharmacokinetics},
year = {2025},
doi = {10.1007/s40262-025-01516-1}
}
EUVIMED